Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer

被引：35
作者：
Fiúza M. [1 ]
机构：
[1] Cardiology Service, Hospital of Santa Maria, University Clinic of Cardiology, Lisbon
来源：
Advances in Therapy | 2009年 / 26卷 / Suppl 1期
关键词：
Breast cancer; Cardiotoxicity; HER2+; Trastuzumab;
D O I：
10.1007/s12325-009-0048-z
中图分类号：
学科分类号：
摘要：
Introduction: Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation. Methods: This paper reviews the cardiotoxicity, associated with trastuzumab use and discusses the risk assessment and management of cardiac dysfunction. Results: The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%). Type II cardiac changes occur in trastuzumab-treated patients, which do not appear to be dose-related, are not associated with histological changes, and are generally reversible. Several risk factors for cardiac events have been identified and assessing levels of troponin I and N-terminal pro-brain B-type natriuretic peptide before and after treatment with trastuzumab may allow early detection of cardiotoxicity. A symptomatic and functional evaluation scheme for patients indicated for treatment with trastuzumab has also been proposed to work alongside therapeutic options for the treatment of heart failure. Conclusion: The risk of cardiac dysfunction associated with trastuzumab can be justified given the increase in overall survival. This risk is lower when trastuzumab is given as monotherapy. The paradigm for cardiologists remains the same: treat the cancer effectively whilst preventing cardiotoxicity. © 2009 Springer Healthcare Communications.
引用
收藏
页码：S9 / S17
页数：8
相关论文
共 36 条
  • [1] Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.-S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, New England Journal of Medicine,
  • [2] Keefe D.L., Trastuzumab-associated cardiotoxicity, Cancer, 95, pp. 1592-1600, (2002)
  • [3] Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.-J., Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007, Annals of Oncology, 18, 7, pp. 1133-1144, (2007)
  • [4] Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L., Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, pp. 177-182, (1987)
  • [5] Hudis C.A., Trastuzumab - Mechanism of action and use in clinical practice, New England Journal of Medicine, 357, 1, pp. 39-51, (2007)
  • [6] Cobleigh M.A., Vogel C.L., Tripathy D., Et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, 17, pp. 2639-2648, (1999)
  • [7] Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2, New England Journal of Medicine, 344, 11, pp. 783-792, (2001)
  • [8] Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton I., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., Extra J.-M., Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group, Journal of Clinical Oncology, 23, 19, pp. 4265-4274, (2005
  • [9] Lin A., Rugo H.S., The role of trastuzumab in early stage breast cancer: Current data and treatment recommendations, Curr Treat Options Oncol, 8, pp. 47-60, (2007)
  • [10] Guarneri V., Lenihan D.J., Valero V., Durand J.-B., Broglio K., Hess K.R., Michaud L.B., Gonzalez-Angulo A.M., Hortobagyi G.N., Esteva F.J., Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience, Journal of Clinical Oncology, 24, 25, pp. 4107-4115, (2006)
1234